The diagnosis of Roche announced the launching of one immunoassay full-automatized for the determination of autoantibodies to cyclical citrullinated peptides (Anti-CCP). Assay was CE approved for the use in the Elecsys/nos systems immunoassay electrochemiluminescence of cobas e. The results of assay of Anti-CCP are intended to be used as one dae (automatic device of entrance) in the diagnosis of the arthritis rheumatoid (in combination with others findings physicians and of the laboratory).
The arthritis rheumatoid is one of the most common illnesses autoimmune, affecting 0,5-1% of the population of the world. This illness systemic is characterized by inflammation chronic of the junctions synovial and degeneration common gradual that leads to the loss of the movement and the exceeding time of deformity. The diagnosis in advance of the arthritis rheumatoid is important because the treatment in advance can help to hinder the common damages and the subsequent inability.
The diagnosis of the arthritis rheumatoid trusts symptoms and clinical tests of laboratory, such as the factor rheumatoid and the C-c-reactive protein. Anti-CCP is superior to both the parameters in the terms of specificity disgnostic and predicts a more severe course and a result of the illness.
“we believe the games of Elecsys Anti-CCP an important paper the diagnosis in advance and the treatment of the arthritis rheumatoid and supply to an excellent tool preliminary doctors and rheumatologists of the care. The test of Elecsys Anti-CCP marks one another successful stage in our strategy to offer to the menu immunoassay the most detailed of the test “, said Dirk Ehlers, head of the diagnosis of the professional of Roche.
On the test
Assay second-generation recently developed of Elecsys Anti-CCP was shown to meet with the disgnostic requirements with excellent sensitivity and specificity in a short total stay of the test of 18 minutes. Assay full-automatized complements the wide menu immunoassay of the diagnosis of Roche in the platforms of Elecsys and cobas and that they allow special the routine use of assays and.
On Roche
Hosted in Basileia, Switzerland, Roche he is one of the research-focused groups leading of healthcare of the world in the fields of pharmaceuticals and the diagnosis. As the company a greatest of biotech of the world and innovator of the products and the services for the advanced detection, the prevention, the diagnosis and the treatment of the illnesses, the group contributes in a wide scale of the front parts to improve the health and the quality of the life person. Roche is the leader of the world in the diagnosis in-vitro and the drugs it to cancer and transplantation, and is a leader of market in virology. Therapeutic is also active in other areas main such as illnesses autoimmune, disorders inflammatory and metabolic and illnesses of the central nervous system. In 2007 vendas for pharmaceuticals the division totalized 36,8 billion frank Swiss, and the division of frank the 9.3 diagnosis affixed vendas of billion. Roche has agreements of the strategical R&D and alliances with numerous partners, including interests of ownership of the majority in Genentech and Chugai, and invested on 8 billion frank Swiss in the R&D in 2007. Worldwide, the group uses 79,000 peoples approximately. The additional information is available in the InterNet in http://www.roche.com.
All the used or mentioned registered marks in this release are protected legally by the law.
Diagnosis LtdRoche.
Forrenstrasse
CH-6343 Rotkreuz
Switzerland
http://www.roche-rotkreuz.com
Filled under: Uncategorized
Leave a comment or two
